|
|
|
|
Learn how Pfizer leveraged wearable digital health technology in their phase 2 trial for cancer cachexia to capture physical activity measures as a secondary endpoint, and how these digital measures played a crucial role in assessing patient-centric outcomes and substantiating the evidence package for regulators, payors, and clinicians.
|
|
|
|
|
Review relevant scientific literature and regulatory guidance to unlock opportunities with DHTs to measure patient-centered outcomes in oncology trials and reduce participation burden, increase the probability of trial success, and improve management of these conditions.
|
|
|
|
|
Learn the essentials of how wearable sensor data from DHTs is used to support efficacy endpoints in regulated clinical trials. We also outline the strategy and key considerations for study teams to successfully navigate this journey from sensor to endpoint.
|
|
|
|
|
Learn how your team can leverage high-frequency and high-fidelity data from DHTs to enable the earlier detection of adverse events like Cytokine Release Syndrome (CRS), and how gathering more standardized data can better characterize these events and treatment response.
|
|
|
|
|
Read about how a digital health solution can provide a deeper understanding of immunotherapy-related challenges in oncology and immunology clinical trials and enable the development of early-warning algorithms to address these challenges.
|
|
|
|
|
We are building the future of clinical trials through patient-focused digital data. Hear directly from our leadership team about how our recently expanded technology and scientific products better support our customers across all trial phases, and how this brings greater insights on both the efficacy and safety of novel therapeutics.
|
|
|
